Supplementary Information Tables: 2014–15 Report on Plans and Priorities
Horizontal Initiatives
Federal Initiative to Address HIV/AIDS in Canada (FI)
Canadian HIV Vaccine Initiative (CHVI)
Federal Initiative to Address HIV/AIDS in Canada (FI)
Name of horizontal initiative: Federal Initiative to Address HIV/AIDS in Canada
Name of Lead Department: Public Health Agency of Canada
Lead department PAA Programs: 1.1 Public Health Infrastructure, and 1.2 Health Promotion and Disease Prevention
Start date of the horizontal initiative: January 13, 2005
End date of the horizontal initiative: Ongoing
Total federal funding allocation (start to end date): Ongoing
Description of the horizontal initiative (including funding agreement): The FI strengthens domestic action on HIV and AIDS, builds a coordinated GoC approach, and supports global health responses to HIV and AIDS. It focuses on research, prevention and access to diagnosis, care, treatment and support for those populations most affected by HIV and AIDS in Canada. The FI also supports and strengthens multi-sectoral partnerships to address the determinants of health. It supports collaborative efforts to address factors which contribute to the transmission and acquisition of HIV. People living with and vulnerable to HIV and AIDS are active partners in FI policies and programs.
Shared Outcomes:
First level outcomes
- Increased knowledge and awareness of the nature of HIV and AIDS and ways to address the disease;
- Increased individual and organizational capacity;
- Increased Canadian engagement and leadership in the global context; and
- Enhanced engagement and collaboration on approaches to address HIV and AIDS.
Second level outcomes
- Reduced stigma, discrimination, and other barriers;
- Improved access to more effective prevention, care, treatment and support;
- Internationally informed federal response; and
- Increased coherence of the federal response.
Ultimate outcomes
- Prevent the acquisition and transmission of new infections;
- Improved quality of life for those at risk and living with HIV and AIDS;
- Contribute to the global effort to reduce the spread of HIV and AIDS and mitigate its impact; and
- Contribute to the strategic outcomes of partner departments.
Governance Structures:
The Responsibility Centre Committee (RCC) is the governance body for the FI. It is comprised of directors or equivalent from the eight responsibility centres which receive funding through the FI. Led by the Agency, the RCC promotes policy and program coherence among the participating departments and agencies, and ensures that evaluation, performance measurement and reporting requirements are met.
The Agency is the federal lead for issues related to HIV and AIDS in Canada. It is responsible for laboratory science, surveillance, program development, knowledge exchange, public awareness, guidance for health professionals, global collaboration and coordination.
Health Canada (HC) supports HIV and AIDS prevention, education and awareness, community capacity building, as well as facilitating access to quality HIV/AIDS diagnosis, care, treatment, and support to on-reserve First Nations and Inuit communities south of the 60th parallel.
As the GoC's agency for health research, the Canadian Institutes of Health Research (CIHR) supports the creation of new scientific knowledge and enables its translation into improved health, more effective health services and products, and a strengthened Canadian health care system.
Correctional Service of Canada (CSC), an agency of the Public Safety Portfolio, provides health services (including services related to the prevention, diagnosis, care and treatment of HIV and AIDS) to offenders sentenced to two years or more.
Planning Highlights: In 2014–15, federal partners will continue to develop integrated approaches to HIV and related communicable diseases and factors such as mental health, aging, chronic diseases, and violence. Programs will address findings from the Federal Initiative Evaluation Report 2008–2013, to strengthen knowledge and exchange mechanisms and enhance efforts to reduce barriers to access to prevention, care, treatment and support programs.
PAA Program | Contributing activities/programs | Total Allocation (from Start to End Date) ($M) |
2014–15 Planned Spending ($M) |
2014–15 Expected Results |
---|---|---|---|---|
Public Health Infrastructure | Public Health Laboratory Systems | Ongoing | 4.9 | ER 1 |
Health Promotion and Disease Prevention | Infectious and Communicable Diseases | Ongoing | 3.6 | ER 2 |
Healthy Communities | Ongoing | 32.1 | ER 3 | |
Total | Ongoing | 40.6 |
Expected Results for 2014–15:
ER 1: Public health decisions and interventions are supported by laboratory reference service testing and the identification of new and existing HIV strains in Canada which directs attention to HIV outbreaks. Use of laboratory-generated knowledge is increased and laboratory research expertise and knowledge platforms are further consolidated, to develop a hub for global leadership in HIV research and viral diagnostics, outbreak response, and genetic linkages to risk of disease.
ER 2:Provinces and territories are engaged through the Public Health Network to increase pan-Canadian understanding of trends and factors associated with HIV and AIDS and related communicable diseases, through enhanced biological-behavioural surveillance, and using this surveillance to guide best practices in prevention and control efforts. Thirteen chapters of the Sexually Transmitted Infections Guidelines will be reviewed and five chapters of the HIV/AIDS Epi Updates publications will be revised.
ER 3: Public health and community capacity is enhanced to prevent and control HIV and AIDS and related communicable diseases, through integrated approaches to HIV and AIDS, related communicable diseases and health factors; renewed stakeholder engagement; targeted information products for key populations; training and knowledge exchange; and global engagement. Community planning sessions will be held for stakeholders to develop partnerships in their province, territory or region. Two series of training modules will be offered to funded organizations to increase their capacity to use community-based social marketing approaches and social media tools to improve the effectiveness of their awareness activities.
PAA Program | Contributing activities/programs | Total Allocation (from Start to End Date) ($M) |
2014–15 Planned Spending ($M) |
2014–15 Expected Results |
---|---|---|---|---|
First Nations and Inuit Primary Health Care | Sexually Transmitted and Blood Borne Infections – HIV/AIDS | Ongoing | 4.5 | ER 4 |
First Nations and Inuit Communicable Disease Control and Management | Support community healthy living programs | Ongoing | 0.3 | ER 4 |
Total | Ongoing | 4.8 |
Expected Results for 2014–15:
ER 4: Development of a national framework that provides strategic direction to Health Canada's STBBI programming to reduce the incidence, prevalence and burden of STBBIs in First Nations on-reserve in partnership with key stakeholders such as First Nations leaders; federal organizations, such as PHAC and CSC; provincial partners; experts and health care workers.
PAA Program | Contributing activities/programs | Total Allocation (from Start to End Date) ($M) |
2014–15 Planned Spending ($M) |
2014–15 Expected Results |
---|---|---|---|---|
Horizontal Health Research Initiatives | Health and Health Service Advances | Ongoing | 20.9 | ER 5.1 ER 5.2 |
Total | Ongoing | 20.9 |
Expected Results for 2014–15:
ER 5.1: Increased knowledge and awareness of the nature of HIV and ways to address the disease through the development and administration of diverse HIV research and capacity building funding programs. In 2014–15, new funding and funding programs will have a focus on providing infrastructure support for multi-disciplinary research networks and advancing research on interventions and their implementation.
ER 5.2: Enhanced coordination, strategic alignment and application of HIV research through the conduct of a strategic planning exercise, engagement of CIHR and Canadian researchers in national and international research endeavours and ongoing partnership development.
PAA Program | Contributing activities/programs | Total Allocation (from Start to End Date) ($M) |
2014–15 Planned Spending ($M) |
2014–15 Expected Results |
---|---|---|---|---|
Custody | Institutional Health Services | Ongoing | 4.2 | ER 6.1 ER 6.2 |
Total | Ongoing | 4.2 |
Expected Results for 2014–15:
ER 6.1: Enhanced understanding of the prevalence of HIV/AIDS, other sexually transmitted and blood borne infections (STBBI) and other communicable diseases, and the prevention of acquisition and transmission of new infections, through screening, assessment and treatment of offenders in federal penitentiaries.
ER 6.2: Increased knowledge and awareness of the nature of HIV/AIDS, other STBBIs and associated chronic diseases and improved access to more effective prevention, care, treatment and support through health surveillance, knowledge transfer to service providers, educational program delivery, distribution of disease prevention information and the provision of disease-specific health clinics within federal penitentiaries.
Total Allocation For All Federal Partners (from Start to End Date) | Total Planned Spending for All Federal Partners for 2014–15 |
---|---|
Ongoing | 70.5 |
Results to be achieved by non-federal partners: International organizations including the Pan-American Health Organization's (PAHO) Caribbean HIV Office, the World Health Organization (WHO), and the United Nations Programme on HIV/AIDS (UNAIDS) increase their capacity to prevent and control HIV and AIDS with the support of Canadian technical assistance and advice, through various working groups and other global knowledge translation and exchange forums.
Contact information:
Marsha Hay-Snyder
Director, Programs and Partnerships Division
613-946-0822
100 Eglantine Drive
Ottawa, ON K1A 0K9
marsha.hay-snyder@phac-aspc.gc.ca
Canadian HIV Vaccine Initiative (CHVI)
Name of horizontal initiative: Canadian HIV Vaccine Initiative
Name of Lead Department: Public Health Agency of Canada
Lead Department PAA Program: 1.2 Health Promotion and Disease Prevention
Start date of the horizontal initiative: February 20, 2007
End date of the horizontal initiative: March 31, 2017
Total Federal Funding Allocation (start to end date): $111M
Description of the horizontal initiative (including funding agreement):
The Canadian HIV Vaccine Initiative (CHVI) is a collaborative undertaking between the GoC and the Bill & Melinda Gates Foundation (BMGF) to contribute to the global effort to develop a safe, effective, affordable and globally accessible HIV vaccine. This collaboration, formalized by a Memorandum of Understanding signed by both parties in August 2006 and renewed in July 2010, builds on the GoC'scommitment to a comprehensive, long-term approach to address HIV/AIDS. Participating federal departments and agencies are the Agency, Health Canada, Industry Canada, Foreign Affairs, Trade and Development Canada, and the Canadian Institutes of Health Research.
The CHVI's overall goals are to: advance the basic science of HIV vaccine discovery and social research in Canada and low- and middle-income countries (LMICs); support the translation of basic science discoveries into clinical research with a focus on accelerating clinical trials in humans; address the enabling conditions to facilitate regulatory approval and community preparedness; improve the efficacy and effectiveness of HIV Prevention of Mother-to-Child services in LMICs by determining innovative strategies and programmatic solutions related to enhancing the accessibility, quality, and uptake; and ensure horizontal collaboration within the CHVI and with domestic and international stakeholders.
Shared Outcomes:
Immediate (1–3 years) Outcomes
- Increased and improved collaboration and networking among researchers working in HIV vaccine discovery and social research in Canada and in LMICs;
- Greater capacity for vaccines research in Canada;
- Enhanced knowledge base; and
- Increased readiness and capacity in Canada and LMICs.
Intermediate Outcomes
- Strengthened contribution to global efforts to accelerate the development of safe effective, affordable, and globally accessible HIV vaccines;
- An increase in the number of women receiving a complete course of anti-retroviral prophylaxis to reduce the risk of mother-to-child transmission of HIV; and
- A strong and vibrant network (the CHVI R&D Alliance) of HIV vaccine researchers and other vaccine researchers, both in Canada and internationally is supported.
Long-term Outcome
- The CHVI contributes to the global efforts to reduce the spread of HIV/AIDS particularly in LMICs.
Governance Structures:
The Minister of Health, in consultation with the Minister of Industry and the Minister of International Development, is the lead for the CHVI. An Advisory Board was established to oversee the implementation of the Memorandum of Understanding between the GoC and the BMGF, and also other duties such as making recommendations to responsible Ministers regarding projects to be funded. The CHVI Secretariat, housed in the Agency, will continue to provide a coordinating role to the GoC and the BMGF.
Planning Highlights: Participating departments and agencies will further initiatives commenced in 2012–13 such as, improving domestic and international research projects, as well as continuing to support the Alliance Coordinating Office.
Plans for 2014–15 include: hosting the 2014 Health Products and Food Branch International Regulatory Forum; continue to support the CHVI Regulatory Capacity Building Mentorship Program; continuing delivery of the Canadian HIV Technology Development Program; exploring monoclonal antibody capacity in Canada; continuing to support implementation research to eliminate mother-to-child transmission of HIV in sub-Saharan Africa; continue to support Canadian research teams working on prevention trials capacity building and on HIV vaccine discovery and social research; developing and launching additional research funding opportunities to continue to advance the basic science of HIV vaccine discovery and social research; and developing and launching the Canadian HIV Vaccine Initiative Translational Support Fund (TSF).
The GoC and the BMGF will continue to work together to define areas of investment to accelerate the development of a safe, effective, affordable and accessible HIV vaccine as one of the key priorities.
PAA Program | Contributing activities/programs | Total Allocation (from Start to End Date) ($M) |
2014–15 Planned Spending ($M) |
2014–15 Expected Results |
---|---|---|---|---|
Health Promotion and Disease Prevention | Healthy Communities | 18.0 Table 1 - Footnote * | 2.5 | ER 1.1 ER 1.2 ER 1.3 ER 1.4 |
Total | 18.0 Table 1 - Footnote * | 2.5 | ||
|
Expected Results for 2014–15:
ER 1.1: Continue to support domestic and international efforts related to the research and development of an HIV vaccine.
ER 1.2: Development and implementation of the HIV Vaccine Translational Support Fund to provide researchers with financial and project management support for translating HIV vaccine candidates from pre-clinical development research to small scale human clinical trials.
ER 1.3: Support the continued work of the Alliance Coordinating Office to establish a strong and vibrant network of HIV vaccine researchers and other vaccine researchers both in Canada and internationally.
ER 1.4: Ensure effective communications, strategic planning, coordination, reporting and evaluation within the GoC.
PAA Program | Contributing activities/programs | Total Allocation (from Start to End Date) ($M) |
2014–15 Planned Spending ($M) |
2014–15 Expected Results |
---|---|---|---|---|
Internal Services | Governance and Management Support Services | 1.0 Table 2 - Footnote * | 0.1 Table 2 - Footnote ** | ER 2.1 |
Health Products | Regulatory Capacity Building Program for HIV Vaccines | 4.0 Table 2 - Footnote * | 0.8 | ER 2.1 ER 3.1 |
Total | 5.0 Table 2 - Footnote * | 0.9 | ||
Expected Results for 2014–15:
ER 2.1: Increased regulatory convergence and exchange of domestic and international best practices, policies and protocols related to the regulation of vaccines, with a focus on HIV/AIDS vaccines.
ER 3.1: Increased regulatory readiness and strengthened capacity of regulatory authorities in LMICs in the area of vaccine products and clinical trials through training and the establishment of a mentorship program.
PAA Program | Contributing activities/programs | Total Allocation (from Start to End Date) ($M) |
2014–15 Planned Spending ($M) |
2014–15 Expected Results |
---|---|---|---|---|
Commercialization and Research and Development Capacity in Targeted Canadian Industries | Industrial Research Assistance Program's Canadian HIV Technology Development Component | 13.0 Table 3 - Footnote * | 3.2 Table 3 - Footnote ** | ER 4.1 |
Total | 13.0 Table 3 - Footnote * | 3.2 Table 3 - Footnote ** | ||
Expected Results for 2014–15:
ER 4.1: New and innovative technologies for the prevention, treatment and diagnosis of HIV in pre-commercial development are advanced in small-and medium-sized enterprises operating in Canada.
PAA Program | Contributing activities/programs | Total Allocation (from Start to End Date) ($M) |
2014–15 Planned Spending ($M) |
2014–15 Expected Results |
---|---|---|---|---|
Global Engagement and Strategic Policy | International Development Assistance Program | 60.0 Table 4 - Footnote * | 6.9 | ER 5.1 ER 5.2 ER 5.3 |
Total | 60.0 Table 4 - Footnote * | 6.9 | ||
|
Expected Results for 2014–15:
ER 5.1: Increased capacity to conduct high-quality clinical trials of HIV vaccine and other related prevention technologies in LMICs through new teams of Canadian and LMICs researchers and research institutions.
ER 5.2: In collaboration with CIHR, increased capacity and greater involvement and collaboration amongst researchers working in HIV vaccine discovery and social research in Canada and in LMICs through the successful completion of the development stage of the Team Grant program to support collaborative teams of Canadian and LMIC researchers.
ER 5.3: Enhanced knowledge of communities, health care workers and Ministry of Health staff in LMICs on the prevention of mother-to-child transmission of HIV and maternal, newborn and child health issues.
PAA Program | Contributing activities/programs | Total Allocation (from Start to End Date) ($M) |
2014–15 Planned Spending ($M) |
2014–15 Expected Results |
---|---|---|---|---|
Health and Health Services Advances | Institute Strategic Advances – HIV/AIDS | 15.0 Table 5 - Footnote * | 2.7 | ER 6.1 ER 6.2 ER 6.3 |
Total | 15.0 Table 5 - Footnote * | 2.7 | ||
|
Expected Results for 2014–15:
ER 6.1: New knowledge created and strengthened HIV vaccine research capacity through ongoing support to CHVI investigators and projects.
ER 6.2: In collaboration with the BMGF, support research addressing the role of mucosal immunology in HIV protection and increase collaborative mucosal immunology research focused on HIV vaccine development.
ER 6.3: Enhanced linkages amongst researchers, stakeholders and funders through participation in collaborative activities (such as the development of a translational research fund); promotion of networking mechanisms (such as those facilitated by the Alliance Coordinating Office; and sharing of research outcomes.
Total Allocation For All Federal Partners (from Start to End Date) | Total Planned Spending for All Federal Partners for 2014–15 |
---|---|
111.0 | 16.2 |
Results to be achieved by non-federal partners: Non-governmental stakeholders, including research institutions and not-for-profit community organizations, are integral to the success of the CHVI. Their role is to engage and collaborate with participating departments and agencies, the BMGF and other funders to contribute to the CHVI goals and to Canada's contribution towards the Global HIV Vaccine Enterprise.
Contact information:
Marc-André Gaudreau
Manager, Strategic Issues
100 Eglantine Driveway
Ottawa, Ontario K1A 0K9
613-952-7199
marc-andre.gaudreau@phac-aspc.gc.ca
Page details
- Date modified: